Abstract:Aims A recent guideline presented by the ESC Congress in 2022 had indicated a novel therapy targeted at pulmonary artery hypertension, known as pulmonary artery denervation (PADN), which get inspired from a laboratorial trial that could lowering the pulmonary artery pressure through the intervention on the animals. Our aim is to conduct a network meta‐analysis to compare the efficacy and safety of PADN from six aspects with the current conventional therapies. Methods and results According to the PRISMA guidance, databases including Ovid, ClinicalTrials.gov, Medline, Embase, and PubMed were searched from inception to 22 August 2023, along with a full assessment of the previous five meta‐analyses. Data were extracted and curated for Bayesian network meta‐analysis. The primary outcome was the change in the 6‐min walking distance (6MWD) from baseline with a secondary outcome called change in mean pulmonary artery pressure (mPAP) from baseline. The four safety outcomes included risk of clinical worsening, hospitalization, mortality and severe adverse events (SAEs). The comparison is structured on a contrast model based on 65 randomized controlled trials (RCTs) on PADN and the other conventional mainstream drugs. PADN had a better effect in improving 6MWD than Placebo (−77.76 m, 95% CI: −102.04 to −54.34 m), Macitentan (−65.32 m, 95% CI: −95.34 to −36.1 m), Bosentan (−64.5 m, 95% CI: −94.7 to −35.07 m), Iloprost (−62.66 m, 95% CI: −99.48 to −27.13 m), Oxygen (−62.42 m, 95% CI: −100.01 to −25.78 m), Treprostinil (−62.01 m, 95% CI: −89.04 to −35.61 m), Riociguat (−60.59 m, 95% CI: −86.11 to −35.98 m), Selexipag (−47.2 m, 95% CI: −85.61 to −10.19 m), Sildenafil (−44.92 m, 95% CI: −74.43 to −16.15 m), or Sitaxsentan (−39.53 m, 95% CI: −78.99 to −0.76 m). PADN had a better antihypertensive effect than placebo and showed statistical significant lower risks to induce clinical worsening and re‐hospitalization than treprostinil, riociguat, and placebo groups. No statistically significant difference in risk of mortality and severe adverse events was observed between PADN versus the other interventions. Conclusions Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual‐drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.

Response to Letter Regarding Article, "hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients with Pulmonary Arterial Hypertension of Different Causes: Phase II Results from the Pulmonary Artery Denervation-1 Study".

Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes

CRT-500.01 Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients with Pulmonary Arterial Hypertension of Different Etiologies: Phase II Results from the PADN-1 Study

Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension: The Single-Center, Prospective, First-in-Man PADN-1 Study (First-in-Man Pulmonary Artery Denervation for Treatment of Pulmonary Artery Hypertension)

Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension

Pulmonary Artery Denervation for Pulmonary Arterial Hypertension A Sham-Controlled Randomized PADN-CFDA Trial

Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta‐analysis

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Treatment Effects of Pulmonary Artery Denervation for Pulmonary Arterial Hypertension Stratified by REVEAL Risk Score: Results from PADN-CFDA Trial

A Sham-Controlled Randomised Trial of Pulmonary Artery Denervation for Group 1 Pulmonary Arterial Hypertension: One-Year Outcomes of the PADN-CFDA Trial

Pulmonary Artery Denervation: Update on Clinical Studies

Update on Pulmonary Artery Denervation for Pulmonary Hypertension

Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomized Trial

Abstract 18284: the Significant Improvement of Cardiac Function after Pulmonary Artery Denervation Procedure in Patients with Pulmonary Arterial Hypertension

EXPRESS: Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure.

Long-term Efficacy of Pulmonary Artery Desnervation Treatment in Heart Failure with Preserved Ejection Fraction: A Subgroup Analysis of 3-Year Results from the PADN-5 Study

The progress of pulmonary artery denervation

Long-term Mortality after Pulmonary Artery Denervation Stratified by Baseline Functional Class in Patients with Pulmonary Arterial Hypertension

Percutaneous Pulmonary Artery Denervation Completely Abolishes Experimental Pulmonary Arterial Hypertension in Vivo.

Assessment and Prognostic Impact of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension Undergoing Pulmonary Artery Denervation: Central Role of Global Right Ventricular Longitudinal Peak Systolic Strain

Pulmonary Artery Denervation Attenuates Pulmonary Arterial Remodeling in Dogs With Pulmonary Arterial Hypertension Induced by Dehydrogenized Monocrotaline.